AMAG Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AMAG Pharmaceuticals Inc.
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
Venture capital funding for biotechs remains aplenty even as listed companies’ stock prices drop. Biogen’s Papadopoulos, Fidelity’s Kaul and Gurnet’s and ex-Sanofi Viehbacher deliberate on whether there is a valuation disconnect and if this is the next "tulip mania."
- Other Names / Subsidiaries
- Advanced Magnetics, Inc.
- Cord Blood Registry (CBR)
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Lumara Health Inc.
- Perosphere Inc.
- Perosphere Pharmaceuticals
- Ther-Rx Corporation